ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2022
Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada.
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 10 citations in OpenAlex.
- Implementation of Genetic Testing in Prostate Cancer: A Real-World Survey of Outpatient Urologists in Germany (PRO-GEN).Cancers · 2026Article
- Breast cancer specialists' experiences and attitudes towards mainstream genetic testing for patients with breast cancer.Hereditary cancer in clinical practice · 2026Article
- Hereditary Prostate Cancer Risk Management: An Evidence-Based Summary to Inform Nursing Practice.Journal of multidisciplinary healthcare · 2026Review
- Germline testing for prostate cancer: current state and opportunities for enhanced access.EBioMedicine · 2025Review
- Guidelines for genetic testing in prostate cancer: a scoping review.Prostate cancer and prostatic diseases · 2024Article
- [Mutation frequency of homologous recombination repair genes in prostate adenocarcinomas].Magyar onkologia · 2024Article
- Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forum.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
- Addressing disparities in cancer clinical trials: a roadmap to more equitable accrual.Frontiers in health services · 2024Article
- Genetic testing practices among specialist physicians who treat prostate cancer A Canadian, cross-sectional survey.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- 2023 Canadian Urological Association guideline: Genetic testing in prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- Metastatic prostate cancer gets into the biomarker era.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGenetic testing in advanced prostate cancer is rapidly moving to become standard of care. Testing for genetic alterations in genes involved in DNA repair pathways, particularly those implicated in the homologous recombination repair (HRR) pathway, in patients with metastatic prostate cancer (mPCa) can inform selection of optimal therapies, as well as provide information about familial cancer risks; however, there are currently no consistent Canadian guidelines in place for genetic testing in mPCa.
methodsA multidisciplinary steering committee guided the process of an environmental scan to define the current landscape, as well as the perceived challenges, through interviews with specialists from 14 sites across Canada. The challenges most commonly identified include limited testing guidelines and protocols, inadequate education and awareness, and insufficient resources. Following the environmental scan, an expert multidisciplinary working group with pan-Canadian representation from medical oncologists, urologists, medical geneticists, genetic counsellors, pathologists, and clinical laboratory scientists convened in virtual meetings to discuss the challenges in implementation of genetic testing in mPCa across Canada.
resultsKey recommendations from the working group include implementation of germline and tumor HRR testing for all patients with mPCa, with a mainstreaming model in which non-geneticist clinicians can initiate germline testing. The working group defined the roles and responsibilities of the various healthcare providers (HCPs) involved in the genetic testing pathway for mPCa patients. In addition, the educational needs for all HCPs involved in the genetic testing pathway for mPCa were defined.
conclusionsAs genetic testing for mPCa becomes standard of care, additional resources and investments will be required to implement the changes that will be needed to support the necessary volume of genetic testing, to ensure equitable access, and to provide education to all stakeholders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.